XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborative Arrangements (Tables)
 9 Months Ended
Sep. 30, 2024
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2024202320242023
Alliance revenue - Lynparza$337 $299 $947 $884 
Alliance revenue - Koselugo39 26 114 74 
Total alliance revenue$376 $325 $1,061 $958 
Cost of sales (1)
82 82 245 230 
Selling, general and administrative39 44 121 143 
Research and development19 23 57 65 
($ in millions)September 30, 2024December 31, 2023
Receivables from AstraZeneca included in Other current assets
$375 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
615 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
— 600 
(1)    Represents amortization of capitalized milestone payments.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2024202320242023
Alliance revenue - Lenvima$251 $260 $755 $734 
Cost of sales (1)
60 137 181 320 
Selling, general and administrative40 46 120 145 
Research and development4 5 18 61 
($ in millions)September 30, 2024December 31, 2023
Receivables from Eisai included in Other current assets
$252 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
— 125 
(1)    Represents amortization of capitalized milestone payments. Amounts in the third quarter and first nine months of 2023 include $81 million and $154 million, respectively, of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2024202320242023
Alliance revenue - Adempas/Verquvo$102 $92 $306 $259 
Net sales of Adempas recorded by Merck72 65 214 189 
Net sales of Verquvo recorded by Merck11 8 25 24 
Total sales$185 $165 $545 $472 
Cost of sales (1)
59 53 182 165 
Selling, general and administrative29 33 88 100 
Research and development27 26 82 76 
($ in millions)September 30, 2024December 31, 2023
Receivables from Bayer included in Other current assets
$166 $156 
Payables to Bayer included in Accrued and other current liabilities
82 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2024202320242023
Net sales of Lagevrio recorded by Merck
$383 $640 $843 $1,236 
Cost of sales (1)
204 348 491 762 
Selling, general and administrative
11 21 43 72 
Research and development
5 8 7 33 
($ in millions)September 30, 2024December 31, 2023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$176 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2024202320242023
Selling, general and administrative $5 $— $21 $— 
Research and development
94 — 227 — 
($ in millions)September 30, 2024December 31, 2023
Payables to Daiichi Sankyo included in Accrued and other current liabilities
$811 $800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities
750 750 
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2024202320242023
Selling, general and administrative $5 $2 $11 $3 
Research and development
93 66 255 153 
($ in millions)September 30, 2024December 31, 2023
Payables to Moderna included in Accrued and other current liabilities
$68 $63